News

TB Alliance Drug,TBA-354, enters Phase I Clinical Trials

19 Feb 2015
by Working Group
Announcements TB Drug Development TB R&D Spotlight Interviews TB Treatment Uncategorized
clinical trials press tb alliance treatment

TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes pretomanid (PA-824). This class of drugs is known to be effective against drug-sensitive and drug-resistant tuberculosis and currently pretomanid is being tested in several clinical trials.

To read the official press release from TB Alliance, click here.

Additional Links

WGND TBA-354 Profile

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis

More News
23 Aug 2022

PAN-TB Collaboration Announces Novel TB Drug Regimens Trial

The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022

WHO Updates Treatment Guidance to Shorter, Novel Regimens for Drug-Resistant Tuberculosis

Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022

Online Consultation on Global Plan to End TB 2023-2030

On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...